细胞免疫参数对结直肠癌的评估价值

Multiparameter analysis of cellular immunity in patients with colorectal cancer

目的:评估结直肠癌患者抗肿瘤免疫状态.方法:应用流式细胞术检测100例未转移结直肠癌患者、100例伴有转移结直肠癌患者和100例健康志愿者外周血CD4+、CD8+、NK、B、CD4+CD25HighCD127lowTreg、Th/Treg值,采用单因素方差分析进行比较,分析差异.结果:转移性结直肠癌患者组分别与正常对照组和非转移性结直肠癌患者组相比,CD4+CD25HighCD127lowTreg细胞升高(7.72%±2.20%vs6.08%±1.47%,5.91%±1.55%,均P<0.05),CD4+T细胞降低(34.04%±8.71%vs37.83%±7.62%,37.68%±8.89%,均P<0.05),Th/Treg值降低(4.70±1.72vs6.47±2.54,6.81±4.09,均P<0.05).结直肠癌患者与正常对照组CD8+T细胞、NK细胞、B细胞三组两两相比,均无统计学意义.结论:转移性结直肠癌患者免疫功能紊乱,主要表现为CD4+T细胞、Th/Treg值降低,CD4+CD25HighCD127lowTreg细胞升高.

AIM： To compare the proportions of CD4＋, CD8＋ T cells, NK cells, B cells, and CD4＋CD25HighCD127low Treg cells and Th/Treg ratio in the peripheral blood of patients with colorectal cancer and healthy controls to investigate the immune status in patients with colorectal cancer.METHODS： Flow cytometry was used to analyze the proportions of CD4＋, CD8＋ T cells, NK cells, B cells, and CD4＋CD25HighCD127low Treg cells and Th/Treg ratio in the peripheral blood from 100 patients with non-metastatic colorectal cancer, 100 patients with metastatic colorectal cancer, and 100 healthy controls. One-way ANOVA was used to study the changes in the above immunity parameters.RESULTS： The proportion of CD4＋CD25HighCD127low Treg cells was significantly higher in patients with metastatic colorectal cancer than in health controls and patients with non-metastatic colorectal cancer （7.72% ± 2.20% vs 6.08% ± 1.47%, 5.91% ± 1.55%, both P 0.05）, while that of CD4＋ T cells was statistically lower in patients with metastatic colorectal cancer than in the other two groups of subjects （34.04% ± 8.71% vs 37.83% ± 7.62%, 37.68% ± 8.89%, both P 0.05）. The Th/Treg ratio was also significantly lower in patients with metastatic colorectal cancer than in health controls and patients with non-metastatic colorectal cancer （4.70 ± 1.72 vs 6.47 ± 2.54, 6.81 ± 4.09, both P 0.05）. There were no statistical differences in the proportions of CD8＋ T cells, NK cells and B cells between patients with colorectal cancer and healthy controls.CONCLUSION： Abnormal immune status was observed in patients with metastatic colorectal cancer.